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Cystic ﬁbrosisRespiratory epithelium is the target of therapies, such as gene therapy, for cystic ﬁbrosis (CF) lung disease. To
determine the usefulness of the nasal epithelium as a pre-screen for lung-directed therapies, we proﬁled gene
expression in CF and non-CF nasal and bronchial epithelium samples using Illumina HumanRef-8 Expression
BeadChips. 863 genes were differentially expressed between CF and non-CF bronchial epithelium but only 15
were differentially expressed between CF and non-CF nasal epithelium (≥1.5-fold, P≤0.05). The most enriched
pathway in CF bronchial epithelium was inﬂammatory response, whereas in CF nasal epithelium it was amino
acid metabolism. We also compared nasal and bronchial epithelium in each group and identiﬁed differential
expression of cellularmovement genes in CF patients and cellular growth genes in non-CF subjects.We conclude
that CF and non-CF nasal and bronchial epithelium are transcriptionally distinct and CF nasal epithelium is not a
good surrogate for the lung respiratory epithelium.on, School of Molecular and
r Medicine Centre, Western
. Fax: +44 131 651 1059.
l rights reserved.© 2011 Elsevier Inc. All rights reserved.1. Introduction
Mutations in the cystic ﬁbrosis transmembrane conductance
regulator (CFTR) gene cause abnormal ﬂuid and ion transport across
the apical membrane of epithelial cells and give rise to lung disease, the
leading cause of morbidity in cystic ﬁbrosis (CF) [1–3]. Nasal respiratory
epithelium displays the CF ion transport abnormality but little, if any,
CF-related pathology [4]. Due to the accessibility of nasal epithelial tissue
much effort has been focussed on using it as a pre-screen for therapies,
such as gene therapy, that target the lungs [5]. Consequently, it is of
relevance to determine in more detail and more globally differences
between CF and non-CF nasal and bronchial epithelium that might
support or contradict the utility of the nasal epithelium as surrogate for
the bronchial epithelium in the assessment of new therapies.
Microarrays enable the analysis of global patterns of gene
expression and are being used to uncover the genomic response to
diseases, such as CF [6]. Microarray analysis of lung tissue from CF
knock-out and control mice revealed differential expression of genes
involved in transcription, inﬂammation, signal transduction, ion
transport and protein trafﬁcking [7]. Two studies proﬁled geneexpression in human airway epithelium. One compared primary
cultures of airway epithelial cells from CF and non-CF donor lungs and
identiﬁed a limited number of differentially expressed genes [8]. A
second study compared nasal epithelium from CF patients with
epithelium from healthy subjects and reported differences in the
expression of genes involved in a wide range of cellular processes,
including protein and lipid turnover, mitochondrial function and
airway defence [9].
Comparison of paired human CF and non-CF native nasal and
bronchial epithelium samples may help to determine whether nasal
epithelium is a suitable surrogate for bronchial epithelium in gene
directed intervention studies. To this end, we undertook an analysis of
global patterns of gene expression in paired freshly brushed nasal and
bronchial epithelium comparing CF patients with healthy controls.
Differentially expressed genes identiﬁed may improve our understand-
ing of the in vivo transcriptional consequences of CFTRmutations in the
respiratory epithelium of the nose and lungs.
2. Results
2.1. Sample cellularity and CFTR expression
A total of 60 airway samples (CF and non-CF nasal and bronchial
epithelium)were used formicroarray analysis (Supplemental Table S1).
A proportion of these were suitable for cytological analysis and
328 V. Ogilvie et al. / Genomics 98 (2011) 327–336immunocytochemistry using CFTR antibodies to assess cell content.
Epithelial cell content ranged from amean of 45% to 79% across the four
sample types with a 5-fold higher percentage of neutrophils in CF
bronchial epithelium samples being the most notable difference
(Table1). Epithelial cells comprised ciliatedornon-ciliated tall columnar
cells but also included goblet cells and basal cells (Supplemental Fig. S1).
Few CF bronchial epithelium samples were of sufﬁcient quality for
immunocytochemistry or cytological analysis andeven suitable samples
were difﬁcult to decipher due to the presence of debris, mucus and
inﬂammatory cells (Supplemental Table S2A). The percentage of
epithelial cells and tall columnar epithelial cells expressing CFTR at the
apical surface was 3-fold higher in non-CF subjects than in CF subjects
(Supplemental Table S2B).
2.2. Global gene expression analysis reveals many differentially expressed
genes in CF bronchial epithelium but few in CF nasal epithelium
We proﬁled gene expression in 8 CF bronchial epithelium samples,
16 non-CF bronchial epithelium samples, 20 CF nasal epithelium
samples and 16 non-CF nasal epithelium samples (Supplemental
Table S1). Using a cut-off of ≥1.5 fold-change and P≤0.05 we found
that 863 genes were differentially expressed between CF and non-CF
bronchial epithelium but only 15 genes were differentially expressed
between CF and non-CF nasal epithelium (Figs. 1A and B). This
represents a 58-fold difference in the proportion of differentially
expressed genes between CF nasal and bronchial epithelium. None of
the differentially expressed genes in CF nasal epithelium reached a
2-fold cut-off whereas 227 genes were differentially expressed by ≥
2-fold in CF bronchial epithelium (P≤0.01).
2.3. Differential gene expression in CF nasal and bronchial epithelium
Since no statistically signiﬁcantly differences were found between
CF and non-CF nasal epithelium samples using a stringent cut-off
(2-fold-change, P≤0.01) we focussed on the genes that passed the
lower cut-off (1.5-fold, P≤0.05) in both CF nasal and bronchial
epithelium samples. Differentially expressed genes encoded proteins
with roles in a wide range of cellular processes. Of the 863
differentially expressed genes in CF bronchial epithelium, 438 were
up-regulated and 425 were down-regulated (Supplemental Table S3).
The most highly up-regulated of these included the putative
lymphocyte G0/G1 switch gene (G0S2), plasminogen activator,
urokinase (PLAU), chemokine receptor 4 (CXCR4), prokineticin 2
(PROK2) and interleukin 8 (IL8) (Table 2A and Supplemental Table
S4). G0S2 encodes a mitochondrial protein and pro-apoptotic factor
that is also an all-trans-retinoic acid target [10]. Plasminogen activator,
urokinase (PLAU) has a critical role in regulating the activity of TGFB1,
involved in tissue repair and ﬁbrosis [11]. CXCR4 is a growth factor
receptor that in response to infection interacts with toll-like receptor 2
(TLR2) in lipid rafts on the apical surface of epithelial cells [12]. PROK2
encodes a secreted protein that is involved in neurogenesis [13]. IL8 is
a potent pro-inﬂammatory cytokine that is also a hallmark of CF lung
inﬂammation [14]. The expression of IL8 is regulated by the
transcription factor, NFKB1, which has a crucial role in regulating
innate immune defences. NFKB1 and several other downstreamTable 1
Cellular content.
% epitheliala
(range)
% macro
(range)
CF BBr (n=3) 45 (38–52) 2 (1–6)
non-CF BBr (n=15) 74 (48–85) 2 (0–8)
CF NBr (n=13) 68 (26–84) 4 (0–10
non-CF NBr (n=15) 79 (50–89) 1 (0–4)
Deﬁnition of abbreviations: BBr=bronchial brushings; NBr=nasal brushings; %=percentag
a Epithelial=ciliated or non-ciliated tall columnar epithelial cells, goblet cells or basal cetargets were up-regulated in CF bronchial epithelium, including TNF,
IL1B, PLAU, PLAUR and the IL2 receptor. Upstreammediators of NFKB1
activation, such as TLR2, RAC1, phosphatidylinisotol-3 kinase (PIK3CA)
and protein kinase B (PTK2B), were also up-regulated. Genes encoding
hypothetical proteinswithhomology to 3RhoGTPases and aRasprotein
activator, as well as 3 transmembrane proteins, were also up-regulated
in CF (Supplemental Table S5). In addition, RNAs encoding multiple
members of the same protein family, such as those encoding proteins
involved in inﬂammation, cell-to-cell signalling and cellular trafﬁcking,
were more abundant in CF bronchial epithelium (Supplemental Table
S6).
Of themost highly down-regulated genes in CF bronchial epithelium
two encoded secretoglobin, secretoglobin family 3A member 1
(SCGB3A1) and secretoglobin family 1A member 1 (SCGB1A1)
(Table 2B and Supplemental Table S4). These genes encode secreted
anti-inﬂammatory cytokines, one of which (SCGB1A1) is known to be
expressed at reduced levels in the induced sputum of CF patients [15].
The other (SCGB3A1) is highly expressed in the airways and has been
shown to be up-regulated during retinoic acid-induced differentiation
of bronchial epithelial cells [16]. Glutathione S-transferase A2 (GSTA2)
is one of four down-regulated glutathione S-transferase enzymeswhich,
along with a further four down-regulated genes encoding cytochrome
P450s (CYPs), perform essential roles in drug metabolism and
detoxiﬁcation (Supplemental Table S6). The calcium-activated chloride
channel, CLCA2, is expressed mainly in basal cells of stratiﬁed epithelia
and has the dual function of mediating chloride conductance and cell-
cell adhesion, and has recently been shown to be a stress-inducible gene
and candidate tumour suppressor [17,18]. Also down-regulated in CF
were RNAs encoding hypothetical proteins with homology to 11 zinc
ﬁnger proteins, two dynein proteins and a sodium/potassium ion
transporter (Supplemental Table S5). A further 11 transcripts encoding
zinc ﬁnger proteins were less abundant in CF bronchial epithelium
(Supplemental Table S6).
Genes differentially expressed in CF nasal epithelium included a
sodium-coupled borate co-transporter (SLC4A11); tubulin alpha 6
(TUBA1C), a major component of microtubules ; claudin 7 (CLDN7), a
tight junction protein that has a role in paracellular ion transport [19];
and beta defensin 1 (DEFB1), an antimicrobial peptide that has an
important role in immune defence and inﬂammation [20] (Table 3).
2.4. Differentially expressed genes common to both CF epithelial tissues
Comparing the differentially expressed genes in CF nasal (n=15
genes) and bronchial epithelium (n=863 genes) we identiﬁed ﬁve
genes in common (Table 3). These were transgelin 2 (TAGLN2),
aldolase A fructose bisphophate transcript variant 2 (ALDOA),
cathepsin D (CTSD), NTS and integral membrane protein 2A
(ITM2A). TAGLN2 is known to be expressed in neoplastic lung
epithelial cells [21]. ALDOA is a glycolytic enzyme bound to the
cytoskeleton which has a role in glucose metabolism and in inducing
lamellipodia formation during keratinocyte migration [22]. NTS is a
neuropeptide which has important physiological roles such as in
increasing pain thresholds and in regulating blood pressure and gut
function [23]. It has also been shown to mediate the production of IL8
upon stimulation by curcumin [24]. CTSD functions as a protease andphage % neutrophil
(range)
% denuded nuclei
(range)
33 (27–44) 20 (10–35)
6 (0–27) 18 (11–26)
) 4 (0–40) 24 (10–49)
2 (0–11) 18 (4–39)
e of total number of nucleated cells counted.
lls.
Fig. 1. Global gene expression proﬁles of CF and non-CF nasal and bronchial epithelium.
RNA from eight CF bronchial epithelial samples, 16 non-CF bronchial epithelial samples,
20 CF nasal epithelial samples and 16 non-CF nasal epithelial sampleswere hybridised to
Illumina HumanRef-8 microarrays displaying probes for 24, 354 genes. Microarray data
were log-transformed and normalised using quantile. After ﬁltering to remove
unreliable genes, 11,080 genes were statistically analysed to identify genes with
signiﬁcant differential expression. Each square represents a different gene. Volcano plots
of (A) CF versus non-CF bronchial epithelium and (B) CF versus non-CF nasal epithelium
(fold-change≥1.5 and Pb0.05). Genes are distributed according to statistical signiﬁ-
cance (y-axis) and magnitude of change (log ratio CF:non-CF) (x-axis). Red squares
represent genes that pass the statistical and fold-change cut-offs (P values were
calculated usingMann–WhitneyU test unpaired andwere corrected formultiple testing
using Benjamini Hochberg False Discovery Rate).
329V. Ogilvie et al. / Genomics 98 (2011) 327–336plays an active role in cytokine-induced programmed cell death [25].
ITM2A is an integral membrane protein found in large cytoplasmic
vehicles and the Golgi apparatus, as well as on the cell surface [26].
These genes were not differentially expressed between CF or non-CF
nasal and bronchial epithelium.2.5. Differential pathways activated in CF versus non-CF nasal and
bronchial epithelium
To identify pathways enriched in the CF tissues we used Ingenuity
Pathways Analysis software to group genes by molecular and cellular
function. Inﬂammatory response was the most signiﬁcant pathway in
CF bronchial epithelium samples, followed by cellular movement and
cell-to-cell signalling and interaction (Table 4). In contrast, amino acid
metabolism, cellular morphology and cellular compromise were the
most signiﬁcant in CF nasal epithelium samples, but these were less
signiﬁcant (Table 4). Together, these pathways indicate that CF
bronchial epithelium has an activated inﬂammatory response and an
increased capacity or need for sensing and mediating cellular
movement compared with non-CF bronchial tissue, whereas CF
nasal epithelium has higher metabolic requirements than non-CF
nasal tissue.
2.6. Differential gene expression in the nasal and bronchial epithelium of
CF patients and healthy subjects
We also compared the gene expression proﬁles of nasal and
bronchial epithelium in each group to identify tissue differences. We
found that the proportion of genes differentially expressed between
paired CF nasal and bronchial epithelium was similar to that of paired
non-CF nasal and bronchial epithelium with 306 and 308 genes
identiﬁed, respectively (Supplemental Tables S7A and S7B). 17% (89
out of 525) of genes differentially expressed between the nasal and
bronchial epithelium of CF patients or healthy subjects overlapped.
Pathway analysis showed that these 89 genes are involved in small
molecular biochemistry, molecular transport and drug and lipid
metabolism. Of the 306 genes differentially expressed between CF
nasal and bronchial epithelium, 174 were up-regulated and 132 were
down-regulated in bronchial epithelial tissue. Between non-CF nasal
and bronchial epithelium 237 out of 308 differentially expressed
genes were up-regulated and 71 were down-regulated in bronchial
epithelial tissue. To determine the maximum, feasible amount of
overlap in differentially expressed genes between nasal and bronchial
epithelium in CF patients and healthy controls we used a fold-change
based gene selection method [27] and identiﬁed a 30% overlap (data
not shown). In CF nasal versus bronchial tissue, the inﬂammatory
response pathwaywas not enriched but pathways involved in cellular
movement, cell-to-cell signalling and interaction and cell signalling
were enriched (Table 5). In contrast, in non-CF nasal versus bronchial
tissue, cellular growth and proliferation, cell cycle and DNA
replication pathways were most enriched, but these were less
signiﬁcant (Table 5).
2.7. QPCR for selected genes conﬁrms microarray data
We selected 10 genes differentially expressed in at least one of the
four comparisons to analyse by QPCR; these were CYP26A1, DUSP5,
FOS, IFITM3, LTF, MMP10, NTS, SCGB1A1, TSC22D3 and TUBGCP4. Two
genes (LTF and MMP10) were selected because they were differen-
tially expressed between nasal and bronchial epithelium in both CF
patients and healthy subjects. Five were differentially expressed
between CF and non-CF bronchial epithelium samples, including
SCGB1A1, one of the top 5 differentially expressed genes in CF
bronchial epithelium. FOS was selected because it was differentially
expressed in three out of the four comparisons. NTSwas one of the ﬁve
genes that overlapped between CF and non-CF nasal and bronchial
epithelium samples. CYP26A1 was selected because it was differen-
tially expressed between the nasal and bronchial epithelium of CF
patients only.We conﬁrmeddifferences in the appropriate tissues for 9
out of 10 genes, the exception was TUBGCP4. Statistically signiﬁcant
changes were conﬁrmed for 7 out of 17 comparisons made. These
included SCGB1A1 (6.3 fold down-regulated in CF versus non-CF
Table 2A
Top 50 genes up-regulated in CF versus non-CF bronchial epithelium.
Gene Symbol Fold change P valuea Accession no.
Putative lymphocyte G0/G1 switch gene G0S2 8.71 0.006 NM_015714.2
Plasminogen activator, urokinase PLAU 8.61 0.002 NM_002658.1
Prokineticin 2 PROK2 6.85 0.003 NM_021935.2
Chemokine (C-X-C motif) receptor 4 CXCR4 6.50 0.004 NM_003467.1
Interleukin 8 IL8 6.35 0.001 NM_000584.2
Chemokine (C-C motif) receptor-like 2 CCRL2 5.62 0.004 NM_003965.3
Serum amyloid A1 SAA1 5.15 0.002 NM_000331.2
Superoxide dismutase 2 SOD2 5.04 0.009 NM_000636.1
S100 calcium binding protein A12 (calgranulin C) S100A12 4.98 0.008 NM_005621.1
Pleckstrin PLEK 4.96 0.004 NM_002664.1
Interleukin 1 IL1B 4.84 0.004 NM_000576.2
Colony stimulating factor 3 receptor (granulocyte) CSF3R 4.82 0.007 NM_172313.1
Tryptase beta 1 TPSAB1 4.56 0.009 NM_003294.2
Interferon ISG15 4.55 0.002 NM_005101.1
Putative chemokine receptor HM74 4.38 0.003 NM_006018.1
Integrin alpha polypeptide ITGAX 4.29 0.004 NM_000887.3
S100 calcium binding protein A9 (calgranulin B) S100A9 4.24 0.005 NM_002965.2
Tumor necrosis factor receptor superfamily TNFRSF1B 4.03 0.009 NM_001066.2
Plasminogen activator, urokinase receptor PLAUR 4.02 0.003 NM_002659.1
Lymphocyte cytosolic protein 1 (L-plastin) LCP1 3.93 0.007 NM_002298.2
Normal mucosa of esophagus speciﬁc 1 C15orf48 3.80 0.003 NM_197955.1
Leukocyte immunoglobulin-like receptor member 3 LILRB3 3.75 0.004 NM_006864.1
Chemokine (C-C motif) ligand 3-like 1 CCL3L1 3.69 0.006 NM_021006.3
Interleukin 1 receptor transcript variant 2 IL1R2 3.65 0.005 NM_173343.1
BCL2-related protein A1 BCL2A1 3.63 0.009 NM_004049.2
Interferon-induced transmembrane protein 1 (9–27) IFITM1 3.56 0.004 NM_003641.2
CD22 antigen CD22 3.52 0.007 NM_001771.1
Leukocyte Ig-like receptor 9 LILRA5 3.51 0.008 NM_021250.2
Pre-B-cell colony enhancing factor 1 NAMPT 3.49 0.006 NM_005746.1
Triggering receptor expressed on myeloid cells 1 TREM1 3.44 0.003 NM_018643.2
Interleukin 1 receptor antagonist IL1RN 3.44 0.002 NM_173842.1
Serum amyloid A2 SAA2 3.44 0.002 NM_030754.2
Matrix metalloproteinase 25 MMP25 3.42 0.004 NM_022468.3
Gardner–Rasheed feline sarcoma viral (v-fgr) oncogene homolog FGR 3.39 0.004 NM_005248.1
Serum amyloid A4 SAA4 3.36 0.003 NM_006512.1
Interferon-induced transmembrane protein 3 (1-8U) IFITM3 3.35 0.002 NM_021034.1
Neutrophil cytosolic factor 1 (47 kDa autosomal 1) NCF1 3.30 0.007 NM_000265.1
Matrix metalloproteinase 9 MMP9 3.30 0.010 NM_004994.1
Prostaglandin-endoperoxide synthase 2 PTGS2 3.26 0.003 NM_000963.1
Hypothetical protein GLT1D1 3.23 0.007 NM_144669.1
Protease inhibitor 3 PI3 3.18 0.005 NM_002638.2
Hypothetical protein LPCAT1 3.12 0.005 NM_024830.3
AXIN1 up-regulated 1 CSRNP1 3.05 0.001 NM_033027.2
Regulator of G-protein signalling 2 RGS2 3.05 0.006 NM_002923.1
Peptidylprolyl isomerase F PPIF 3.05 0.001 NM_005729.3
CD83 antigen CD83 2.96 0.004 NM_004233.2
Cytidine deaminase CDA 2.95 0.006 NM_001785.1
Tumor necrosis factor (ligand) superfamily TNFSF13B 2.93 0.003 NM_006573.3
Interferon-induced protein with tetratricopeptide repeats 4 IFIT3 2.88 0.005 NM_001549.2
Pleckstrin homology binding protein CYTIP 2.84 0.004 NM_004288.2
Deﬁnition of abbreviations: Fold-change, mean ratio (CF:non-CF); P-value≤0.01 (corrected for multiple testing using Benjamini Hochberg False Discovery Rate).
a The full list of genes most highly up-regulated in CF versus non-CF bronchial epithelium can be found in Supplemental Table S4 (≥2-fold, P≤0.01).
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bronchial versus nasal epithelium, P=0.0004); CYP26A1 (3.6 fold
down-regulated in CF bronchial versus nasal epithelium, P=0.0008);
and NTS (2.1-fold down-regulated in CF versus non-CF bronchial
epithelium but was of borderline statistical signiﬁcance, P=0.056 and
2.7 fold down-regulated in CF versus non-CF nasal epithelium,
P=0.0073) (Fig. 2).
2.8. Microarrays can distinguish CF patients and healthy subjects by
their bronchial epithelial tissue but not by their nasal epithelial tissue
A heatmap generated by unsupervised hierarchical clustering of
the 24 bronchial epithelium samples and the 227 most differentially
expressed genes demonstrated that CF patients and healthy subjects
could be distinguished by the gene expression proﬁles of their
bronchial epithelium (Fig. 3). In comparison, clustering of the 36 nasal
samples and the 15 differentially expressed genes that passedmoderately stringent ﬁlters was inadequate, resulting in two groups
that consisted of 16 CF patients (80%) and 4 healthy subjects, and 11
healthy subjects (69%) and 2 CF patients (Supplemental Fig. S2). There
was no obvious correlation with age, gender or recent infection;
however, a group of nine CF nasal samples clustered by the batch in
which they were processed. Clustering the bronchial epithelium
samples by the expression patterns of the same 15 genes was also
ineffective in distinguishing CF patients and healthy subjects (data not
shown).
3. Discussion
In this study of global patterns of gene expression in samples from
the nasal and bronchial epithelium of CF patients and healthy
controls, we provide evidence that suggests caution in the use of
nasal epithelium as a pre-screen for lung-directed therapies, such as
gene therapy or novel CF therapeutics.
Table 2B
Top 50 genes down-regulated in CF versus non-CF bronchial epithelium.
Gene Symbol Fold-change P valuea Accession no.
Secretoglobin, family 3A, member 1 SCGB3A1 5.22 0.002 NM_052863.1
Secretoglobin, family 1A, member 1 SCGB1A1 5.11 0.001 NM_003357.3
Glutathione S-transferase A2 GSTA2 4.41 0.001 NM_000846.3
Chloride channel family member 2 CLCA2 3.41 0.002 NM_006536.3
Neurotensin NTS 3.25 0.009 NM_006183.3
BTB (POZ) domain containing 5 KLHL28 2.98 0.001 NM_017658.1
ATPase lysosomal 56/58 kDa ATP6V1B1 2.93 0.001 NM_001692.2
Cytochrome P450 subfamily J CYP2J2 2.82 0.001 NM_000775.2
DMC1 dosage suppressor of mck1 homolog DMC1 2.81 0.002 NM_007068.2
Zinc ﬁnger protein 14 (KOX 6) ZNF14 2.81 0.001 NM_021030.2
Hypothetical protein FLJ34047 2.75 0.001 NM_173669.1
Activator of S phase kinase DBF4 2.74 0.002 NM_006716.3
Gamma tubulin ring complex protein TUBGCP4 2.72 0.001 NM_014444.2
Transcriptional adaptor 3 (NGG1 homolog transcript variant 2) TADA3 2.71 0.001 NM_133480.1
Hypothetical protein FLJ34278 2.70 0.001 NM_173602.1
Claudin 8 CLDN8 2.67 0.002 NM_012132.3
Glutathione S-transferase A5 GSTA5 2.62 0.002 NM_153699.1
Protein S (alpha) PROS1 2.62 0.003 NM_000313.1
Alcohol dehydrogenase 1A (class I) ADH1A 2.61 0.004 NM_000667.2
ATP-binding cassette member 13 ABCC13 2.61 0.002 NM_172024.1
Hypothetical zinc ﬁnger protein ZNF667 2.60 0.001 NM_022103.2
SLIT and NTRK-like family SLITRK6 2.59 0.001 NM_032229.2
Hypothetical protein C19orf39 2.59 0.001 NM_175871.2
Interleukin 18 (interferon-gamma-inducing factor) IL18 2.59 0.001 NM_001562.2
Hypothetical protein FLJ20700 2.54 0.001 NM_017932.1
Small nuclear RNA activating complex 43 kDa SNAPC1 2.52 0.001 NM_003082.2
Golgin-67 GOLGA8A 2.51 0.002 NM_181077.1
FLJ35093 protein FAM73A 2.50 0.001 NM_198549.1
Erythrocyte transmembrane protein LOC51145 2.47 0.001 NM_016158.1
Hypothetical protein LOC286177 2.47 0.001 XM_379582.1
Similar to alpha tubulin LOC375049 2.43 0.002 XM_351316.1
Aldehyde dehydrogenase 1 family ALDH1A1 2.42 0.003 NM_000689.3
Tripartite motif-containing 50C TRIM74 2.41 0.001 NM_198853.1
Keratin 15 KRT15 2.40 0.008 NM_002275.2
Alcohol dehydrogenase 1C (class I) ADH1C 2.40 0.005 NM_000669.2
Chromosome 14 open reading frame 127 (C14orf127) NUBPL 2.39 0.001 NM_025152.1
NADH dehydrogenase (ubiquinone) 12 NDUFC2 2.38 0.001 NM_004549.3
FK506 binding protein 14 FKBP14 2.38 0.002 NM_017946.1
CD164 antigen CD164 2.37 0.003 NM_006016.3
Hypothetical protein FAM55B 2.36 0.001 NM_182495.3
Zinc ﬁnger protein 339 OVOL2 2.35 0.001 NM_021220.1
Hypothetical LOC91170 2.35 0.001 XM_036612.8
Similar to CG9117-PA MBLAC1 2.35 0.001 XM_171171.2
Hydroxysteroid (17-beta) dehydrogenase 7 HSD17B7 2.33 0.001 NM_016371.1
Hypothetical protein FLJ21657 C5orf28 2.32 0.002 NM_022483.2
Folate receptor 1 (adult) FOLR1 2.29 0.003 NM_016731.2
Protocadherin beta 9 PCDHB9 2.29 0.002 NM_019119.3
Nuclear factor of activated T-cells NFATC3 2.28 0.001 NM_173164.1
Basic leucine zipper nuclear factor 1 (JEM-1) BLZF1 2.28 0.002 NM_003666.2
Flavoprotein oxidoreductase MICAL3 2.28 0.001 XM_032997.4
Deﬁnition of abbreviations: Fold-change, mean ratio (CF:non-CF); P-value≤0.01 (corrected for multiple testing using Benjamini Hochberg False Discovery Rate).
a The full list of genes most highly down-regulated in CF versus non-CF bronchial epithelium can be found in Supplemental Table S4 (≥2-fold, P≤0.01).
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bronchial respiratory epithelium [28,29], we hypothesized that they
would display similar global patterns of gene expression. However,
we show that they have different patterns of differential gene
expression, with little overlap between the two tissues. One reason
for this difference might be that there is little, if any, CF-related
pathology in CF nasal epithelium whereas there is signiﬁcant
pathology in CF bronchial epithelium e.g. chronic infection and
neutrophil-dominated inﬂammation [30]. Also, mucociliary clearance
in the nose has been shown to be normal unless signiﬁcant sinonasal
disease is present [31]. Enrichment in CF versus non-CF bronchial
epithelium, but not in CF versus non-CF nasal epithelium, of pathways
involved in the inﬂammatory response and immune cell trafﬁcking
support this at the molecular level. A second possible reason for the
difference is that CF bronchial epithelium samples contain a higher
proportion of neutrophils (33%) than non-CF bronchial epithelium
samples (6%) or CF nasal samples (4%) such that non-epithelial cells
might contribute to the overall signal obtained in CF bronchialepithelium samples. However, a survey of the literature on global
analysis of gene expression in neutrophils revealed that only 22 of the
863 genes (2.5%) differentially expressed in CF bronchial epithelium
were reported to be differentially expressed in either human CF
neutrophils or stimulated neutrophils; including, beta actin (ACTB),
pre-B cell enhancing factor CXCL10, FOS, heat shock protein 70
(HSP70), IL8, IL1B and CTSD [32,33]. A third possible reason might be
that there is a greater diversity of epithelial subtypes in the bronchial
versus nasal epithelium samples. Fourthly, the chronic effects of
ﬁbrosis and airway remodelling, downstream of infection and
inﬂammation, in the lung may account for the differences.
With respect to the proportion of differentially expressed genes
identiﬁed in CF nasal and bronchial epithelium, our work contrasts
with that of others who have proﬁled gene expression in human CF
airway epithelial tissue. In a study of primary cultures of airway
epithelial cells from CF and non-CF donor lung tissue 24 differentially
expressed genes (0.1% of genes analysed) were identiﬁed [8]. This
contrasts with the 863 genes (3.5% of genes analysed) that we found
Table 3
Differentially expressed genes in CF versus non-CF nasal epithelium.
Gene Symbol Fold-change P valuea Accession no.
NADH dehydrogenase 1 MT-ND1 2.29 0.037 NM_173708.1
Calcyphosine transcript variant 1 CAPS 1.82 0.040 NM_004058.2
Transgelin 2 TAGLN2 1.78 0.028 NM_003564.1
Aldolase A fructose bisphosphate transcript variant 2 ALDOA 1.68 0.037 NM_184041.1
Claudin 7 CLDN7 1.67 0.032 NM_001307.3
Solute carrier family 4 member 11 SLC4A11 1.65 0.032 NM_032034.1
Insulin-like growth factor binding protein 2 (36kD) IGFBP2 1.58 0.046 NM_000597.1
Cathepsin D (lysosomal aspartyl protease) CTSD 1.57 0.032 NM_001909.3
Aldo-keto reductase family 1 AKR1B1 1.56 0.003 NM_001628.2
β defensin-1 DEFB1 1.56 0.034 NM_005218.2
Tubulin alpha 6 TUBA1C 1.54 0.037 NM_032704.2
Junction plakoglobin mRNA JUP 1.51 0.038 NM_021991.1
Calcineurin homologous protein LOC63928 0.41 0.032 NM_022097.1
Neurotensin NTS 0.47 0.037 NM_006183.3
Integral membrane protein 2A ITM2A 0.65 0.032 NM_004867.2
Deﬁnition of abbreviations: Fold-change, mean ratio (CF:non-CF); P-value≤0.05 (corrected for multiple testing using Benjamini Hochberg False Discovery Rate). Italics, genes
differentially expressed between CF and non-CF bronchial epithelium.
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epithelium. Even the 227 differentially expressed genes that passed
stringent ﬁltering represent a 9-fold larger proportion of differentially
expressed genes than those reported by Zabner et al. [8]. As the
authors analysed resting cultures of differentiated airway epithelial
cells grown at air-liquid interface the in vitro culture conditions used
in this study may explain why they reported minimal CF and non-CF
differences. Our results in which we identify many differences
between freshly brushed CF and non-CF bronchial epithelium samples
likely reﬂect the complex patterns of airway epithelial cell gene
expression in physiologically relevant lung milieu.
In a second microarray study, 0.15%–1.27% of genes analysed were
reported to be differentially expressed [9]. This contrasts with the 15
genes (0.06% of genes analysed) we found to be differentially
expressed in CF nasal epithelium. One reason for the difference may
be that 7 out of the 8 patients included in our study were undergoing
antibiotic treatment at the time of brushing. More likely, however, are
the differences in study design, the patient cohort and the stringency
of cut-offs applied.
There is some overlap in the differentially expressed genes
reported in our study and those reported in the studies cited above.
Although none of the differentially expressed genes reported by
Zabner et al. [8] were identical to those in CF bronchial epithelium,
there were eight genes out of 11 known genes with functions inTable 4
Pathways enriched in CF versus non-CF airway epithelium.
Molecular and cellular pathways
CF bronchial epithelium P value
Inﬂammatory response 1.18E−36
Cellular movement 1.66E−29
Cell-to-cell signalling and interaction 3.38E−26
Immune cell trafﬁcking 5.58E−24
Cellular growth and proliferation 2.98E−23
Hematological system development and function 6.71E−23
Cell death 3.58E−21
Tissue development 5.28E−20
Cellular development 2.91E−19
Connective tissue disorders 3.38E−19
CF nasal epithelium
Amino acid metabolism 1.15E−02
Cell morphology 3.07E−02
Cellular compromise 3.93E−02
Drug metabolism 3.85E−02
Molecular transport 4.87E−02
Deﬁnition of abbreviations: P value, gene network generated by IPA and ranked
according to the presence of differentially expressed genes within a curated gene
network. The ﬁvemost signiﬁcant gene networks in each category are shown (P≤0.05).common. Analogous genes in CF bronchial epitheliumencoded proteins
involved in ion transport, lipid and amino acid metabolism, signal
transduction, cell-to-cell signalling and inﬂammation (the exceptions
were Copine VII (CPNE7), transferrin receptor (TF) and topoisomerase I
(TOP1)). In terms of CF nasal epithelium, integralmembrane protein 2A
(ITM2A), a gene encoding a T lymphocyte-inducible integralmembrane
protein, has also been reported to be down-regulated in CF nasal
epithelium from patients with low lung function (Wright et al. [9]).
ITM2A and ﬁve further genes (ACTB, CD74, interferon-induced
transmembrane protein 1 (IFITM1), SP110 nuclear body protein and
epithelial stromal interaction protein 1 (EPSTI1)) were also differen-
tially expressed in CF bronchial epithelium. Furthermore, as for CF
bronchial epithelium,Wright et al. [9] reporteddifferential expressionof
genes involved in a wide range of cellular processes, including protein
and lipid turnover, mitochondrial function and airway defence. It is
noteworthy that 10 genes differentially expressed in CF bronchial
epithelium were differentially expressed in CF mouse knock-out lung
tissue [7]. Additionally, the authors reported differential expression of
genes involved in a wide range of cellular processes, including
transcription, inﬂammation, signal transduction, ion transport and
protein trafﬁcking. Overall, the overlap between our transcriptome data
and that of the studies cited above supports the general view that data
from different platforms can give rise to concordant differentially
expressed genes and pathways [27].
To identify tissue differences between nasal and bronchial
epithelium we compared the expression proﬁles of these tissues in
CF patients and in healthy subjects. We showed that a similarTable 5
Pathways enriched in bronchial versus nasal epithelium of CF patients and healthy
subjects.
Molecular and cellular pathways
CF patients P value
Cellular movement 1.37E−24
Cell-to-cell signalling and interaction 1.48E−16
Cell signaling 5.94E−16
Molecular transport 5.94E−16
Vitamin and mineral metabolism 5.94E−16
Healthy subjects
Cellular growth and proliferation 7.44E−04
Cell cycle 1.27E−03
DNA replication, recombination and repair 1.27E−03
Antigen presentation 6.05E−03
Cell morphology 6.05E−03
Deﬁnition of abbreviations: P value, gene network generated by IPA and ranked
according to the presence of differentially expressed genes within a curated gene
network. The ﬁvemost signiﬁcant gene networks in each category are shown (P≤0.05).
Fig. 2. Selected genes analysed by quantitative real-time PCR (QPCR). QPCR analysis of gene expression in CF and non-CF nasal and bronchial epithelium was performed using
TaqMan assays (Applied Biosystems) for (A) cytochrome P450 (CYP26A1), (B) lactoferrin (LTF), (C) matrix metalloproteinase 10 (MMP10), (D) neurotensin (NTS) and (E)
secretoglobin (SCGB1A1). RNA levels are normalised to large ribosomal protein 0 (RPLP0). The sample with the lowest relative expression value in the four conditions was used as
the calibrator (1×) sample. Data are plotted on a log scale. Statistical analysis was performed using Prism 4.0. software (GraphPad, San Diego, USA). P≤0.05 was considered
statistically signiﬁcant (Mann–Whitney unpaired test). *, P≤0.05, ** Pb0.01, *** Pb0.001.
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tissues and between the non-CF tissues but that the majority (83%) of
genes did not overlap. Pathways involved in tissue repair, such as
cellular movement and cell-to-cell signalling, were differentially
expressed between CF nasal and bronchial epithelium samples but
were not differentially expressed between non-CF nasal and bronchial
epithelium samples where pathways involved in tissue maintenance,
such as cellular growth and proliferation, were enriched. These results
indicate that CF and healthy nasal and bronchial epithelium have
differential functions in vivo. Furthermore, some of the differentially
expressed genes and perturbed pathways in patient airways suggest
that the bronchial epithelium is adapting to its environment byinitiating cellular changes that may eventually lead to epithelial
metaplasia. For example, the gene SCGB1A1 is known as a Clara cell
marker (although it is also expressed by other cell types) and is down-
regulated in CF bronchial epithelium comparedwith non-CF bronchial
epithelium but is expressed at similar levels to both CF and non-CF
nasal epithelium (Fig. 2). This could suggest that CF bronchial
epithelium has a drastically reduced Clara cell content since the
nasal epithelium lacks Clara cells. Changes in the epithelial phenotype
of CF airways, such as changes in the proportion, morphology or gene
expression patterns of Clara cells or goblet cells, have been proposed
to contribute to the development of chronic lung disease in CF but
studies of goblet cells have yielded conﬂicting results [34–36]. Our
334 V. Ogilvie et al. / Genomics 98 (2011) 327–336transcriptome data revealed discordant patterns of expression for
goblet cell markers, MUC1 and MUC5B, in CF nasal versus bronchial
epithelium (Supplemental Table S7A). Cellular changes may explain
some of the differences in global patterns of gene expression between
CF and non-CF nasal and bronchial epithelium. Strikingly, the
inﬂammatory response pathway was only enriched when CF and
non-CF bronchial epithelium were compared. This suggests that only
bronchial tissue will be useful in predicting the inﬂammatory
response of the lung to new treatments, such as gene therapy.
Notably, the nose has not proved useful as a surrogate for the lung
with regards to toxicity in a recent gene therapy study [37]. As
children's lungs may be more amenable to treatment than adults’
lungs it might be expected that changes in the inﬂammatory proﬁle of
bronchial epitheliummay bemore readily detected in children than in
adults after treatment.
Given the heterogeneity of CF lung disease, we were surprised to
ﬁnd highly consistent patterns of gene expression in the bronchial
epithelium, but not the nasal epithelium, of individuals of the same
group. These results suggest thatmicroarrays can detect altered global
gene expression in CF bronchial epithelium samples but may be less
informative in CF nasal epithelium samples due to the limited number
of genes with detectable changes in this tissue. QPCR may be better
suited to the analysis of gene expression in CF nasal epithelium in the
study of new CF therapies, such as gene therapy, because it is highly
sensitive and enables detailed analysis of a small number of genes.
Difﬁculties in identifying a consistently expressed reference gene for
nasal epithelial tissue will need to be overcome if this approach is
taken. However, our results do not negate the utility of nasal
epithelium as a model tissue for the direct assessment of CFTR gene
transfer.
It was important to identify differences between CF and non-CF
nasal and bronchial epithelial tissue because successful CF therapies
might be expected to induce changes in the expression levels of the
genes we have identiﬁed towards non-CF levels. By establishing CF
and non-CF differences in nasal and bronchial epithelial tissuewemay
be able to understand the biological signiﬁcance of changes in global
patterns of gene expression in these tissues after treatment. Our
results lay the foundation for the development of a focussed,
hypothesis-driven approach to microarray analysis of bronchial
epithelium in the study of lung-directed therapies, such as gene
therapy. Microarrays are being used for a similar purpose in cancer
treatment studies [38]. It is noteworthy that the vast majority of genes
did not show statistically signiﬁcant differential expression in CF nasal
or bronchial epithelium (99.9% and 96.5% of genes analysed,
respectively) indicating that the detectable in vivo transcriptional
consequences of CFTR mutations in respiratory epithelium are
minimal. We were unable to gather sufﬁcient differential data from
CF versus non-CF bronchial epithelium samples using immunocyto-
chemical CFTR antibodies to allow us to draw any robust conclusions.
This was due to the limited number of CF bronchial epithelium
samples of sufﬁcient quality for detailed cellular analysis.
A potential limitation of our study is that CF bronchial epithelium
samples were obtained under general anaesthetic whereas non-CF
bronchial samples, and nasal samples, were not. There was also a
signiﬁcant age difference between CF patients and healthy subjects.
Therefore, some of the CF and non-CF differences identiﬁed may beFig. 3. Heatmap of bronchial epithelium samples. A heatmap was generated by
unsupervised hierarchical clustering of 277 genes (fold-change≥2.0, P≤0.01) and
bronchial samples (n=8 CF patients, n=16 non-CF subjects) using Euclidean distance
and average linkage rule. Branch length indicates the degree of similarity between
samples (top) and genes (right side) where short branches indicate high similarity.
After clustering, samples were decoded to identify CF patients (red branches) and non-
CF healthy people (blue branches). Red bars indicate up-regulation in CF. Green bars
indicate downregulation in CF. Black indicates no differential expression (fold-
changeb2.0, PN0.01).
335V. Ogilvie et al. / Genomics 98 (2011) 327–336age-related or due to anaesthetic but the effects of these factors are
likely to be low compared with the effects of the disease itself. Use of
paired nasal and bronchial epithelium samples from CF patients and
healthy subjects was more pertinent to the hypothesis being tested in
this study.
Our exploratory results highlight the need to consider alternative
methods of sampling the bronchial epithelium from patients
undergoing bronchoscopy. Given the cost and effort involved in
generating transcriptome data from CF patients it is important that
optimal approaches for sample collection and handling are agreed on
for future studies. Our ﬁndings have important implications not only
for microarray analysis of gene expression but also for new rapidly
evolving proﬁling technologies, such as next generation sequencing.
In conclusion, our results do not support the use of the nasal
epithelium as a pre-screen for lung-directed therapies due to
differences in global patterns of gene expression between CF and
non-CF nasal and bronchial epithelium samples. However, the CF
nasal epithelium may have some use in predicting the molecular
response to new treatments, such as gene therapy or novel CF
therapeutics e.g. in identifying genes most proximal to the primary
genetic defect. Our results suggest that bronchial epithelium samples
should be directly used to assess the biological effects of new
treatments on inﬂammation in the lung.4. Materials and methods
4.1. Nasal and bronchial brushings
CF had been diagnosed on standard criteria [39] and 23 out of 28
were homozygous for the ΔF508 mutation; 2 were compound
heterozygotes for theΔF508mutation; and 3were sweat test-positive
but had not been genotyped. Healthy volunteers had been screened
for CFTRmutations, were free of any respiratory tract symptoms, were
non-smokers and had no allergies. Protocols had been approved by
the local Research Ethics Committee and informed written consent
(and where appropriate, assent for children) had been obtained from
the subjects. Additional detail on the subjects can be found in
Supplemental Tables S8 and S9. Bronchial brushings were obtained by
bronchoscopy from ﬁve airways of approximately 5-6th generation
using a cytology brush (Olympus BD-202D-5010). Nasal brushings
were obtained from themucosal surface of the inferior turbinate using
a 2.7 mm interdental brush (Dent-O-Care, London, UK Ltd.). Immu-
nocytochemistry was used to determine epithelial cell content, as
previously described [40]. Brushings were double-stained using
cytokeratin and CFTR (G449; [41]) antibodies. Cellular content was
determined by cytological analysis.4.2. RNA preparation and microarray hybridisation
Total RNA was extracted using RNeasy mini columns (Qiagen Ltd.,
Crawley, UK) and treated with DNase I (DNA-free kit, Applied
Biosystems™, Warrington, UK). RNA quality and quantity was
determined using a 2100 Bioanalyser, according to manufacturers’
instructions (Agilent Technologies UK Ltd., Wokingham, UK). An RNA
Integrity Number (RIN) ranging from a mean of 6.6±2.6 to 8.8±1.0
indicated quality (Supplemental Table S10). Biotin-labelled, antisense
copy RNA (cRNA) was synthesised from 100 ng of total RNA
(Illumina® TotalPrep RNA Ampliﬁcation kit, Cat. No. IL1791, Ambion,
UK) as described by the manufacturer. 850 ng of cRNAwas hybridised
to a Sentrix HumanRef-8 v1 Expression BeadChip microarray accord-
ing to manufacturer's instructions (Illumina® San Diego, USA).
Microarrays were scanned using a BeadArray Reader (Illumina®)
and data were processed using BeadStudio software v2 (Illumina®).
Additional detail on the methods is provided in supplementary data.4.3. Microarray data analysis
Data were analysed using GeneSpring GX10 software (Agilent
Technologies), and results conﬁrmed by limma [42] and SAM [43]
analyses using R [44] and Bioconductor [45] (Supplemental Fig. S3).
Data were normalised by Quantile and ﬁltered. Signiﬁcant changes
were calculated by the Mann–Whitney U test unpaired and P values
were corrected for multiple testing using Benjamini–Hochburg false
discovery rate. Additional detail on the method is provided in
supplementary data. Ingenuity pathway analysis software (Ingenuity
Systems Inc., www.ingenuity.com) was used to identify signiﬁcant
pathways. The Basic Local Alignment Search Tool (BLAST) was used to
identify homologues (≥90% identity) for genes encoding hypothetical
proteins.
4.4. Quantitative real-time polymerase chain reaction (QPCR)
100 ng of cRNA was reverse transcribed using random hexamer
primers and a ﬁrst-strand cDNA synthesis kit for RT-PCR (Roche,West
Sussex, UK). cDNA was quantiﬁed by PicoGreen (PicoGreen dsDNA
assay kit, Molecular Probes®, Paisley, UK). QPCR was performed using
TaqMan® Universal PCR Mastermix and gene-speciﬁc assays on an
ABI 7900HT Fast Real-Time PCR system (Applied Biosystems™,
Warrington, UK). Additional detail on the method is provided in
supplementary data.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.ygeno.2011.06.008.
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